Literature DB >> 23207773

Effect of nafamostat on N-methyl-D-aspartate-induced retinal neuronal and capillary degeneration in rats.

Yo Tsuda1, Tsutomu Nakahara, Kaori Ueda, Asami Mori, Kenji Sakamoto, Kunio Ishii.   

Abstract

We examined the effects of the serine protease inhibitor nafamostat mesilate on neuronal and vascular injury in rat retinas treated with N-methyl-D-aspartate (NMDA). The degree of neuronal degeneration was assessed by measuring the number of cells in the ganglion cell layer and the thickness of the inner plexiform layer. The degree of capillary degeneration was assessed by measuring the number of empty basement membrane sleeves that were left as remnants of the vessels. Significant neuronal and capillary degeneration was observed 7 d after a single intravitreal injection of NMDA into the eye. Both forms of degeneration were significantly prevented by simultaneous injection of nafamostat mesilate with NMDA. These results indicate that nafamostat mesilate affords protection against the neuro/vascular injury seen in NMDA-treated retinas. Nafamostat mesilate may be considered as a candidate for neuro/vascular protective interventions in retinal diseases associated with glutamate-induced excitotoxicity, such as glaucoma and diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23207773     DOI: 10.1248/bpb.b12-00644

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  OCT angiography, RNFL and the visual field at different values of intraocular pressure.

Authors:  Jakub Kral; Jan Lestak; Elena Nutterova
Journal:  Biomed Rep       Date:  2022-03-02

2.  Nafamostat and sepimostat identified as novel neuroprotective agents via NR2B N-methyl-D-aspartate receptor antagonism using a rat retinal excitotoxicity model.

Authors:  Masahiro Fuwa; Masaaki Kageyama; Koji Ohashi; Masaaki Sasaoka; Ryuichi Sato; Masami Tanaka; Kei Tashiro
Journal:  Sci Rep       Date:  2019-12-31       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.